文献速递神经核医学肿瘤 PET/CT

11C-乙酸PET/CT检测反应性星形胶质增生有助于胶质瘤分类

11 C-Acetate PET/CT Detects Reactive Astrogliosis Helping Glioma Classification.
PubMed 文献 · Clin Nucl Med · 2022-07-26

这项前瞻性研究纳入182例术前接受11C-乙酸PET/CT的胶质瘤患者,计算肿瘤SUVmax与对侧脉络丛SUVmean比值(11C-ACE TCR)。IDH1野生型肿瘤TCR中位数显著高于突变型(2.38 vs 1.30,P<0.001);IDH1野生型中分级的AUC为0.951,高于突变型的0.783(P=0.002)。高11C-乙酸摄取与高级别IDH1野生型肿瘤相关。

要点

  • IDH1野生型胶质瘤的11C-ACE TCR中位数显著高于IDH1突变型(2.38 vs 1.30,P<0.001)。
  • IDH1野生型肿瘤分级AUC为0.951,高于IDH1突变型的0.783(P=0.002)。
  • 少突胶质细胞瘤的低11C-乙酸摄取有助于克服放射性氨基酸示踪剂的局限。

核心结论

  • 高11C-乙酸摄取与高级别IDH1野生型肿瘤相关,有助于与高级别IDH1突变型和低级别胶质瘤鉴别。

研究设计与样本

  • 前瞻性研究,共182例患者术前接受11C-乙酸PET/CT,计算肿瘤SUVmax与对侧脉络丛SUVmean比值(11C-ACE TCR)。

主要发现

  • IDH1野生型肿瘤(n=91)的11C-ACE TCR中位数显著高于IDH1突变型肿瘤(n=91)(2.38 vs 1.30,P<0.001)。
  • 91例IDH1突变型肿瘤中,少突胶质细胞瘤与星形细胞肿瘤的11C-ACE TCR中位数无差异(1.40 vs 1.20,P>0.05)。
  • 低级别与高级别胶质瘤分级的ROC分析显示,IDH1野生型肿瘤的AUC为0.951,高于IDH1突变型肿瘤的0.783(P=0.002)。
  • 3级少突胶质细胞瘤的11C-ACE TCR显著低于IDH1野生型胶质母细胞瘤。

关键数值与推荐

  • 2级为低级别肿瘤,3级和4级为高级别肿瘤。
  • IDH1野生型肿瘤11C-ACE TCR中位数2.38,IDH1突变型1.30(P<0.001)。
  • IDH1突变型中少突胶质细胞瘤TCR中位数1.40,星形细胞肿瘤1.20(P>0.05)。
  • IDH1野生型分级AUC 0.951,IDH1突变型0.783(P=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 11 C-acetate ( 11 C-ACE) uptake on PET/CT was recently discovered to represent reactive astrocytes in the tumor microenvironment. This study aimed at evaluating the role of 11 C-ACE PET/CT as an imaging biomarker of reactive astrogliosis in characterizing different types of gliomas. METHODS: In this prospective study, a total of 182 patients underwent 11 C-ACE PET/CT before surgery. The ratio of SUV max of a glioma to the SUV mean of the contralateral choroid plexus ( 11 C-ACE TCR) on PET/CT was calculated. 11 C-ACE TCRs were compared with the World Health Organization grades and isocitrate dehydrogenase 1 ( IDH1 ) mutation status. Grade 2 was considered low-grade tumor, and grades 3 and 4 were considered high-grade tumors. RESULTS: The median 11 C-ACE TCR was significantly higher in IDH1 wild-type (wt) tumors (n = 91) than in IDH1 -mutant (mt) tumors (n = 91) (2.38 vs 1.30, P < 0.001). Of the 91 IDH1 -mt tumors, there were no differences in the median 11 C-ACE TCRs between oligodendrogliomas (ODs) and astrocytic tumors (1.40 vs 1.20, P > 0.05). In grading low- versus high-grade gliomas, the receiver operating characteristic curve analyses showed a higher area under the curve (0.951) in IDH1 -wt tumors than in IDH1 -mt tumors (0.783, P = 0.002). Grade 2 ODs were well differentiated from high-grade gliomas. The 11 C-ACE TCR of grade 3 ODs was significantly lower than that of IDH1 -wt glioblastomas. CONCLUSIONS: High 11 C-ACE uptake is associated with high-grade IDH1 -wt tumors, thus facilitating differentiation from high-grade IDH1-mt and low-grade gliomas. In particular, low 11 C-ACE uptake in ODs is advantageous in overcoming the limitation of radiolabeled amino acid tracers.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kim D, Chun JH, Yi JH, et al. 11 C-Acetate PET/CT Detects Reactive Astrogliosis Helping Glioma Classification. Clin Nucl Med. 2022. PMID: 35868002. doi:10.1097/RLU.0000000000004341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。